- Home
- BMR vs ACET Comparison
BMR vs ACET Comparison
Compare BMR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMR
- ACET
- Stock Information
- Founded
- BMR 2009
- ACET 1947
- Country
- BMR Israel
- ACET United States
- Employees
- BMR N/A
- ACET N/A
- Industry
- BMR Computer Software: Prepackaged Software
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- BMR Technology
- ACET Health Care
- Exchange
- BMR Nasdaq
- ACET Nasdaq
- Market Cap
- BMR 59.3M
- ACET 64.9M
- IPO Year
- BMR 2023
- ACET N/A
- Fundamental
- Price
- BMR $3.35
- ACET $0.61
- Analyst Decision
- BMR
- ACET Buy
- Analyst Count
- BMR 0
- ACET 6
- Target Price
- BMR N/A
- ACET $6.00
- AVG Volume (30 Days)
- BMR 1.0M
- ACET 398.4K
- Earning Date
- BMR 08-05-2025
- ACET 08-12-2025
- Dividend Yield
- BMR N/A
- ACET N/A
- EPS Growth
- BMR N/A
- ACET N/A
- EPS
- BMR N/A
- ACET N/A
- Revenue
- BMR $3,064,000.00
- ACET N/A
- Revenue This Year
- BMR $21.21
- ACET N/A
- Revenue Next Year
- BMR N/A
- ACET N/A
- P/E Ratio
- BMR N/A
- ACET N/A
- Revenue Growth
- BMR 5.33
- ACET N/A
- 52 Week Low
- BMR $1.86
- ACET $0.45
- 52 Week High
- BMR $6.59
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- BMR 59.12
- ACET 38.76
- Support Level
- BMR $2.98
- ACET $0.61
- Resistance Level
- BMR $3.20
- ACET $0.69
- Average True Range (ATR)
- BMR 0.22
- ACET 0.04
- MACD
- BMR -0.01
- ACET -0.01
- Stochastic Oscillator
- BMR 88.33
- ACET 12.80
About BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.